87 related articles for article (PubMed ID: 14978929)
1. [Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Takeshita A
Rinsho Ketsueki; 2003 Dec; 44(12):1133-43. PubMed ID: 14978929
[No Abstract] [Full Text] [Related]
2. [Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Ohnishi K
Rinsho Ketsueki; 2006 Aug; 47(8):717-23. PubMed ID: 16986710
[No Abstract] [Full Text] [Related]
3. [Current treatment of acute myeloid leukaemia in adults].
Telek B; Rejto L; Kiss A; Batár P; Reményi G; Szász R; Ujj ZÁ; Udvardy M
Orv Hetil; 2012 Feb; 153(7):243-9. PubMed ID: 22318524
[TBL] [Abstract][Full Text] [Related]
4. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Tallman M
Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
[No Abstract] [Full Text] [Related]
5. [Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia].
Usui N
Rinsho Ketsueki; 2007 Jun; 48(6):458-67. PubMed ID: 17633093
[No Abstract] [Full Text] [Related]
6. Current management and new approaches in the treatment of APL.
Tallman MS
Clin Adv Hematol Oncol; 2003 Oct; 1(10):580-1. PubMed ID: 16258453
[No Abstract] [Full Text] [Related]
7. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Tallman MS
Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
[TBL] [Abstract][Full Text] [Related]
8. Acute myelogenous leukemia presenting as acute infectious meningitis in a 7-year-old boy.
D'Orazio JA; Burns LA; Farhoudi N; McBride MT; Kesler MV
Clin Pediatr (Phila); 2009 May; 48(4):444-8. PubMed ID: 19224868
[No Abstract] [Full Text] [Related]
9. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
[TBL] [Abstract][Full Text] [Related]
10. [Antileukemic].
Inomata T; Sunami K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():191-4. PubMed ID: 25831750
[No Abstract] [Full Text] [Related]
11. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
14. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Tsimberidou A; Estey E; Cortes J; Thomas D; Faderl S; Verstovsek S; Garcia-Manero G; Keating M; Albitar M; O'Brien S; Kantarjian H; Giles F
Cancer; 2003 Mar; 97(6):1481-7. PubMed ID: 12627513
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
Doyen J; Italiano A; Peyrade F; Bouyer C; Thyss A
Br J Haematol; 2008 May; 141(5):744-5. PubMed ID: 18373704
[No Abstract] [Full Text] [Related]
16. A case report of acute myeloid leukemia after liver transplantation.
Liu M; Liu J; Liu L; Yu L; Shi B; Ye L; Zhang Y; Chen H
Acta Haematol; 2013; 129(4):225-8. PubMed ID: 23295767
[TBL] [Abstract][Full Text] [Related]
17. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
[TBL] [Abstract][Full Text] [Related]
18. Acute myelogenous leukemia associated with Ollier disease.
White MS; Martin PL; McLean TW
Pediatr Blood Cancer; 2008 Mar; 50(3):645-6. PubMed ID: 16991136
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
[No Abstract] [Full Text] [Related]
20. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
Lichtman MA
Blood Cells Mol Dis; 2013 Feb; 50(2):119-30. PubMed ID: 23154039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
